Trends in Immunology, Год журнала: 2019, Номер 40(4), С. 310 - 327
Опубликована: Март 17, 2019
Язык: Английский
Trends in Immunology, Год журнала: 2019, Номер 40(4), С. 310 - 327
Опубликована: Март 17, 2019
Язык: Английский
Cancer Discovery, Год журнала: 2018, Номер 8(9), С. 1069 - 1086
Опубликована: Авг. 16, 2018
Immune checkpoint blockade is able to induce durable responses across multiple types of cancer, which has enabled the oncology community begin envision potentially curative therapeutic approaches. However, remarkable immunotherapies are currently limited a minority patients and indications, highlighting need for more effective novel Indeed, an extraordinary amount preclinical clinical investigation exploring potential negative positive costimulatory molecules. Insights into underlying biological mechanisms functions these molecules have, however, lagged significantly behind. Such understanding will be essential rational design next-generation immunotherapies. Here, we review current state our T-cell blockade, primarily CTLA4 PD-1, highlight conceptual gaps in knowledge.Significance: This provides overview immune therapy from basic biology immunologic perspective cancer research community. Cancer Discov; 8(9); 1069-86. ©2018 AACR.
Язык: Английский
Процитировано
2616Chemical Society Reviews, Год журнала: 2018, Номер 48(7), С. 2053 - 2108
Опубликована: Сен. 27, 2018
The nonradiative conversion of light energy into heat (photothermal therapy, PTT) or sound (photoacoustic imaging, PAI) has been intensively investigated for the treatment and diagnosis cancer, respectively. By taking advantage nanocarriers, both imaging therapeutic functions together with enhanced tumour accumulation have thoroughly studied to improve pre-clinical efficiency PAI PTT. In this review, we first summarize development inorganic organic nano photothermal transduction agents (PTAs) strategies improving PTT outcomes, including applying appropriate laser dosage, guiding via techniques, developing PTAs absorption in second NIR window, increasing (PCE), also tumours. Second, introduce advantages combining other therapies cancer treatment. Third, emerging applications cancer-related research are exemplified. Finally, perspectives challenges combating especially regarding their clinical translation, discussed. We believe that having noteworthy features would become promising next-generation non-invasive theranostic techniques our ability combat cancers.
Язык: Английский
Процитировано
2498Nature Reviews Drug Discovery, Год журнала: 2019, Номер 18(3), С. 175 - 196
Опубликована: Янв. 8, 2019
Язык: Английский
Процитировано
2151Nature, Год журнала: 2019, Номер 575(7782), С. 299 - 309
Опубликована: Ноя. 13, 2019
Язык: Английский
Процитировано
2096Bioinformatics, Год журнала: 2019, Номер 35(20), С. 4200 - 4202
Опубликована: Март 20, 2019
The interaction between tumor and immune system plays a crucial role in both cancer development treatment response. To facilitate comprehensive investigation of tumor-immune interactions, we have designed user-friendly web portal TISIDB, which integrated multiple types data resources oncoimmunology. First, manually curated 4176 records from 2530 publications, reported 988 genes related to anti-tumor immunity. Second, associated with the resistance or sensitivity cells T cell-mediated killing immunotherapy were identified by analyzing high-throughput screening genomic profiling data. Third, associations any gene features, such as lymphocytes, immunomodulators chemokines, pre-calculated for 30 TCGA types. In biologists can cross-check interest about its interactions through literature mining analysis, generate testable hypotheses high quality figures publication.http://cis.hku.hk/TISIDB.Supplementary are available at Bioinformatics online.
Язык: Английский
Процитировано
1866Annual Review of Pathology Mechanisms of Disease, Год журнала: 2020, Номер 16(1), С. 223 - 249
Опубликована: Ноя. 16, 2020
Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer immunotherapy. Starting with approval anti-cytotoxic T lymphocyte-associated protein 4 (anti-CTLA-4) for advanced-stage melanoma 2011, ICIs-which now also include antibodies against programmed cell death 1 (PD-1) and its ligand (PD-L1)-quickly gained US Food Drug Administration treatment a wide array types, demonstrating unprecedented extension patient survival. However, despite success ICIs, resistance to these agents restricts number patients able achieve durable responses, immune-related adverse events complicate treatment. Thus, better understanding requirements effective safe antitumor immune response following ICI therapy is needed. Studies both tumoral systemic changes system yielded insight into basis efficacy resistance. Ultimately, by building on insights, researchers should be combine ICIs other agents, or design new immunotherapies, broader more as well greater safety. Here, we review history clinical utility mechanisms therapy, local associated outcome.
Язык: Английский
Процитировано
1617Annual Review of Immunology, Год журнала: 2019, Номер 37(1), С. 457 - 495
Опубликована: Янв. 24, 2019
Exhausted CD8 T (Tex) cells are a distinct cell lineage that arise during chronic infections and cancers in animal models humans. Tex characterized by progressive loss of effector functions, high sustained inhibitory receptor expression, metabolic dysregulation, poor memory recall homeostatic self-renewal, transcriptional epigenetic programs. The ability to reinvigorate through blockade, such as αPD-1, highlights the therapeutic potential targeting this population. Emerging insights into mechanisms exhaustion informing immunotherapies for cancer infections. However, like other immune cells, heterogeneous include progenitor terminal subsets with unique characteristics responses checkpoint blockade. Here, we review our current understanding biology, including developmental paths, features, intrinsic extrinsic factors contributing how knowledge may inform infections, autoimmunity, cancer.
Язык: Английский
Процитировано
1519Nature reviews. Cancer, Год журнала: 2019, Номер 19(6), С. 307 - 325
Опубликована: Май 15, 2019
Язык: Английский
Процитировано
1326Pharmacology & Therapeutics, Год журнала: 2020, Номер 221, С. 107753 - 107753
Опубликована: Ноя. 28, 2020
Язык: Английский
Процитировано
1285Immunity, Год журнала: 2019, Номер 50(1), С. 195 - 211.e10
Опубликована: Янв. 1, 2019
Язык: Английский
Процитировано
1267